Key result
Patients in all stages of chronic kidney disease had significantly lower plasma nitric oxide levels compared to healthy controls, with levels progressively decreasing as renal failure advanced.
Why the study?
Are nitric oxide and related biomarker levels altered in patients with different stages of chronic kidney disease compared to healthy controls?
Cross-Sectional (n=100)
No
Are nitric oxide and related biomarker levels altered in patients with different stages of chronic kidney disease compared to healthy controls?
Nitric oxide production is decreased across all stages of CKD, likely due to increased ADMA and decreased L-arginine, contributing to endothelial dysfunction and increased cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May link nitric oxide depletion to endothelial dysfunction in CKD; hypothesis-generating and requires prospective validation before clinical adoption.
Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular (CVD) morbidity and mortality, mainly due to atherosclerosis. Decreased production or reduced bioavailability of nitric oxide (NO) can result in endothelial dysfunction (ED). Multiple mechanisms are known to cause a state of NO deficiency in patients with CKD. Patients in various stages of CKD grouped as group-1 (CKD stage 1 and 2), group-2 (CKD stage 3 and 4), group-3 (CKD stage 5) and healthy controls were included in the study. Each group of patients and controls comprised 25 subjects. Plasma nitrites, L-arginine, asymmetric dimethyl arginine (ADMA) and citrulline were measured in all the subjects. Patients in all stages of CKD had lower NO and higher ADMA levels compared to controls. Further, group-2 and group-3 patients had lower levels of NO and higher levels of ADMA than group-1 patients. L-arginine levels showed no difference between patients and controls. However, group-3 patients had lower L-arginine levels compared to group-1 patients. Citrulline levels were decreased in group-3 patients. NO production was decreased in patients in all stages of CKD. The decrease could be due to decreased availability of the substrate, L-arginine or due to an increased ADMA, a potent inhibitor of endothelial NO synthase. Therapeutic interventions directed towards improvement of NO production in addition to management of other CVD risk factors may prevent development of ED and facilitate proper management of CKD patients who are at increased risk for CVD.
No takes yet. Share an insight, caveat, or question.
Rao et al. (2014) conducted a cross-sectional in Chronic kidney disease (n=100). Chronic kidney disease vs. Healthy controls was evaluated on Plasma nitric oxide (NO) levels (µmol/L) (p=<0.001). Patients in all stages of chronic kidney disease had significantly lower plasma nitric oxide levels compared to healthy controls, with levels progressively decreasing as renal failure advanced.
Synapse has enriched 10 related papers. Consider them for comparative context: